Distinguished Guest Lecture Nov 16 by Dr. Özlem Türeci: RNA-based therapeutics and personalized neoantigen cancer vaccines
Dr. Özlem Türeci, Chief Medical Officer, BioNTech and Professor, Mainz University Medical Ctr & Helmholtz Institute for Translational Oncology visits Radiumhospitalet/OCC on November 16th to give a lecture.
Time and place: – , Radiumhospitalet/OCC, Kaare Norum Auditorium
NB: Registration necessary
Dr. Tureci will also give a talk at 1800 the same day in the Norwegian Academy of Science and Letters with title: “Vaccines: mRNA vaccine technology - COVID-19, Cancer & beyond”.
Abstract from dr. Türeci:
My talk at Oslo University Hospital will be a scientific, technological one directed to an expert scientific and clinical audience with strong background in immunology and oncology.
My talk at Oslo University Hospital will be a scientific, technological one directed to an expert scientific and clinical audience with strong background in immunology and oncology.
I may cover 2 topics if time allows: preclinical-clinical development of RNA cancer vaccines and a new CAR T cell
Registration: https://nettskjema.
See also announcement from PRIMA - a Center of Excellence in Precision Immunotherapy:
Organizers:
Institute for Cancer Research, Oslo University Hospital, CoE PRIMA, University of Oslo and Norwegian Society for Immunology
Institute for Cancer Research, Oslo University Hospital, CoE PRIMA, University of Oslo and Norwegian Society for Immunology
Contacts: kjetil.tasken@medisin.uio.no and johanna.olweus@medisin.uio.no
NB: Dr. Tureci will also give a talk at 1800 in the Norwegian Academy of Science and Letters with the title:
Vaccines: mRNA vaccine technology - COVID-19, Cancer & beyond
The The Norwegian Academy of Science and Letters talk will cover the development of mRNA vaccine technology and the journey from cancer vaccines to the Pfizer/BioNTech Covid vaccine.